Announcements Trials

Browse Landscape

Phase

Phase 3 1 Phase 2 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 2 Stomach Neoplasms 1 Psychological Well-Being 1 Pancreatic Neoplasms 1 Motor Activity 1 Lung Neoplasms 1 Liver Neoplasms 1 Leiomyoma 1 Inflammation 1 Esophageal Neoplasms 1 Carcinoma, Hepatocellular 1 Agnosia 1 Abdominal Cancer 1

Interventions

relugolix 8 ulipristal acetate 7 telapristone acetate 7 estradiol, norethindrone drug combination 7 vilaprisan 6 asoprisnil 6 Estradiol 5 linzagolix 4 elagolix 4 Norethindrone Acetate 3 Leuprolide 3 Sugars 2 Progestins 2 epigallocatechin gallate 1 Uterine Myomectomy 1 Uterine Artery Embolization 1 Tranexamic Acid 1 Tea 1 Standard of Care 1 Sodium Chloride 1 Saline Solution 1 Misoprostol 1 Mifepristone 1 Megestrol Acetate 1 Medroxyprogesterone Acetate 1 Laparoscopy 1 Iron 1 Hysterectomy 1 Goserelin 1 Gonadotropin-Releasing Hormone 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Leiomyoma × Tea × Clear all

NCT05364008 2026-03-23

FRIEND

Yale University

Phase 3 Active not recruiting

Leiomyoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡